About Bikam Pharmaceuticals
Bikam Pharmaceuticals is a Healthcare company based in Cambridge (United States) founded in 2007, and was acquired by Shire in July 2014. Small molecule therapeutics for degenerative eye diseases were developed. Bikam Pharmaceuticals has raised $11 million across 2 funding rounds from investors including Takeda Pharmaceuticals, CHL Medical Partners and Healthcare Ventures. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified. Its competitors include Kriya Therapeutics, Annexon and Aldeyra; 3 of its 3 listed competitors have raised funding.
Company details
Bikam Pharmaceuticals was founded in 2007 in Cambridge, United States, within the biotechnology sector. Focus was placed on developing small molecule therapeutics targeting degenerative eye diseases. A lead compound, functioning as a pharmacological chaperone, was examined for preserving photoreceptor cell function in autosomal dominant retinitis pigmentosa. Operations centered on preclinical investigations. In July 2014, acquisition by Shire occurred for 2.5 million upfront, plus potential milestones up to 92 million.
- Headquarters Cambridge, United States
- Stage Acquired
- SectorsHealthcare
- Website bikampharmaceuticals.com
- Acquired by Shire (Jul 2014)
- Total Equity Funding$11M (USD)
in 2 rounds
- Latest Funding Round$11M (USD), Series A
Nov 2007
- InvestorsTakeda Pharmaceuticals
& 3 more
- Acquired byShire
(Jul 2014)
Funding Insights of Bikam Pharmaceuticals
Bikam Pharmaceuticals has successfully raised a total of $11M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $11 million completed in November 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11M
- Total Rounds 2
- Last Round Series A — $11M
- Investors Count 3
All 2 funding rounds of Bikam Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2007 | $11M | Series A | – | CHL Medical Partners, Healthcare Ventures | – |
| Jun 2007 | Series A | – | – |
4 investors in total: 4 institutional.
Investors in Bikam Pharmaceuticals
Bikam Pharmaceuticals has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals, CHL Medical Partners and Healthcare Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage healthcare services investments are facilitated by CHL. | chlmedical.com | Westport, United States | ||
| hcven.com | ||||
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Rare disease treatments are developed by a specialty biopharmaceutical firm. | 1986 | shire.com | Dublin, Ireland |
Investor details for Bikam Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Bikam Pharmaceuticals
4 dated milestones of Bikam Pharmaceuticals across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Bikam Pharmaceuticals is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $11.0M.
- Exit Acquired by Shire.
Competitors of Bikam Pharmaceuticals
Bikam Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Annexon and Aldeyra.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. |
Detailed competitors of Bikam Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as Bikam Pharmaceuticals (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bikam Pharmaceuticals
Complete news archive for Bikam Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bikam Pharmaceuticals
Bikam Pharmaceuticals was founded in 2007.
Bikam Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Bikam Pharmaceuticals is a funded company, having raised a total of $11M across 2 funding rounds to date.
Bikam Pharmaceuticals was founded in 2007 in Cambridge, United States, within the biotechnology sector. Focus was placed on developing small molecule therapeutics targeting degenerative eye diseases. A lead compound, functioning as a pharmacological chaperone, was examined for preserving photoreceptor cell function in autosomal dominant retinitis pigmentosa. Operations centered on preclinical investigations. In July 2014, acquisition by Shire occurred for 2.5 million upfront, plus potential milestones up to 92 million.
Bikam Pharmaceuticals's top competitors include Annexon, Aldeyra and Kriya Therapeutics.
Bikam Pharmaceuticals has 4 investors. Key investors include Takeda Pharmaceuticals, CHL Medical Partners, Healthcare Ventures, and F-Prime Capital.
Yes. Bikam Pharmaceuticals was acquired by Shire in July 2014.